Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 115
Titolo Tipologia Data di pubblicazione Autori File
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 02 - Intervento a convegno 2023 Gotuzzo, ICazzaniga, MDe Bernardi, ECicchiello, FCordani, NCerrito, MTurolla, ELandoni, CCrivellaro, CVirdone, LMonaco, LGuerra, L +
A second update on mapping the human genetic architecture of COVID-19 01 - Articolo su rivista 2023 Invernizzi, PietroGerussi, AlessioBiondi, AndreaBellani, GiacomoBellelli, GiuseppeCiterio, GiuseppeFoti, GiuseppeBettini, Laura RacheleValsecchi, Maria G.Cazzaniga, MarinaFaverio, PaolaBonfanti, Paolo +
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 01 - Articolo su rivista 2023 Nicoletta CordaniGiuseppe PagliaRamona MeantiMaria Grazia CerritoChiara VillaMario MauriLuca MologniAntonio TorselloMarina Elena Cazzaniga +
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 01 - Articolo su rivista 2023 Cazzaniga, Marina EBonfanti, Paolo +
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 01 - Articolo su rivista 2023 Nicoletta CordaniLuca MologniRocco PiazzaPietro TettamantiMario MauriMatteo VillaFederica MalighettiCamillo Di BellaMaria Grazia CerritoGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 02 - Intervento a convegno 2023 Nicoletta CordaniLuca MologniRocco PiazzaCamillo Di BellaMaria Grazia CerritoMatteo VillaGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 01 - Articolo su rivista 2023 Cazzaniga M. E. +
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 01 - Articolo su rivista 2023 Bonfanti P.Cazzaniga M. E. +
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 01 - Articolo su rivista 2023 Cordani N.Bianchi T.Cortinovis D. L.Cazzaniga M. E.Lissoni A. A.Landoni F. +
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial 01 - Articolo su rivista 2022 Cazzaniga, Marina +
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 01 - Articolo su rivista 2022 Cicchiello F.Cordani N.Cerrito M. G.Cazzaniga M. E. +
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 01 - Articolo su rivista 2022 Russo, SelenaBani, MarcoTerraneo, MarcoNuvolati, GiampaoloCazzaniga, Marina ElenaStrepparava, Maria Grazia +
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 01 - Articolo su rivista 2022 Marina Elena CazzanigaNicoletta CordaniMaria Grazia Cerrito +
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 01 - Articolo su rivista 2022 Pagan, EleonoraBagnardi, VincenzoCazzaniga, Marina Elena +
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 01 - Articolo su rivista 2022 Scagliotti A.Capizzi L.Cazzaniga M. E.Ilari A.Cordani N.Albini A.Lavitrano M.Grassilli E.Cerrito M. G. +
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 01 - Articolo su rivista 2022 Terraneo, MarcoNuvolati, GiampaoloBani, MarcoRusso, SelenaStrepparava, Maria GraziaCazzaniga, Marina Elena +
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 01 - Articolo su rivista 2022 Gerussi, AlessioBiondi, AndreaBinatti, EleonoraBellani, GiacomoBellelli, GiuseppeCiterio, GiuseppeFoti, GiuseppeBettini, Laura RacheleValsecchi, Maria GraziaD'Angiò, MariellaCazzaniga, MarinaFaverio, PaolaBonfanti, PaoloInvernizzi, Pietro +
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 01 - Articolo su rivista 2022 Cazzaniga M. E.Baroni S.Cicchiello F.Cordani N.Cerrito M. G. +
Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything 01 - Articolo su rivista 2022 Cazzaniga, Marina Elena +
Mostrati risultati da 1 a 20 di 115
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile